ENDRA Life Sciences Inc. has filed its quarterly report, providing insights into its financial performance for the third quarter of 2026. This update is significant as it highlights the company's ongoing developments in the electromedical and electrotherapeutic apparatus sector.
Based in Ann Arbor, Michigan, ENDRA Life Sciences operates under the Standard Industrial Classification (SIC) code 3845, which pertains to electromedical and electrotherapeutic apparatus. The company is publicly traded on the Nasdaq under the ticker symbol NDRA. The latest filing, a Form 10-Q, was submitted on November 16, 2026, and covers the financial period ending September 30, 2026.
The filing details various financial metrics that are crucial for stakeholders. While specific figures were not disclosed in the available filing text, it typically includes revenue, expenses, and net income or loss, which are vital for assessing the company's financial health. The report is expected to shed light on how ENDRA is managing its resources and navigating the competitive landscape.
This quarterly report may have implications for various stakeholders, including investors, analysts, and competitors. Investors will be particularly interested in how the reported metrics align with market expectations and the company's strategic goals. Competitors within the electromedical sector will also be monitoring ENDRA's performance to gauge market trends and potential shifts in consumer demand.
What's next for ENDRA Life Sciences remains to be seen. The filing does not specify any upcoming events or actions that the company will take following this report. However, stakeholders will likely be awaiting further updates as the company continues to evolve in the dynamic electromedical industry.
For more detailed information, the full filing can be accessed through the SEC's website, under accession number 0001213900-26-120776.
Read Next
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates
Comscore Reports Strong Q3 Results with Revenue Growth





